Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds
Novartis captured attention last week for its Phase III prostate cancer win with a radioligand therapy it picked up for $2 billion back in 2018 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
